Overview
DARE market data
Price History
DARE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -679.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.13 – $3.78 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $20.3M · P/B 9.70 · P/S 17.22.
Company News
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Aug 14, 2026, 5:06 PM
Dare Bioscience Shares Halted On Circuit Breaker To The Downside, Stock Now Up -16.79%Benzinga · Aug 14, 2026, 4:47 PM
Daré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/ShareBenzinga · Aug 14, 2026, 4:47 PM
Dare Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 14, 2026, 1:11 PM
Dare Bioscience Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 13, 2026, 9:25 PM
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K EstimateBenzinga · Aug 13, 2026, 8:02 PM
8-K filing — Dare Bioscience, Inc. (DARE)SEC EDGAR · Jul 24, 2026, 1:00 PM
Dare Biosciences Receives Second $1M Tranche Of NIH FundingBenzinga · May 26, 2026, 12:15 PM
Daré Bioscience Initiates Phase 2 Clinical Study Of DARE-HPV TreatmentBenzinga · May 18, 2026, 12:05 PM
Dare Bioscience Q1 2026 Earnings Call: Complete TranscriptBenzinga · May 14, 2026, 9:37 PM